Antimicrobial Nanocoating

6.项目摘要/摘要医院内(医院获得性)感染是最主要的 医疗保健行业面临的严重问题。在收购的大约200万家医院中 在这个国家每年报告的感染中，大约有一半与导管、输尿管支架、 中心线和其他经皮装置，为生物体提供供追踪进入的支撑面 更深层的组织。一种典型的感染可能需要每个患者高达4.7万美元的治疗费用。虽然是侵略性的 医疗器械，如支架和导尿管，预先消毒并插入或植入 大多数无菌条件可用；生物被膜生长、结垢和后续感染是最常见的 常见的故障模式。可以使这些设备对生物膜具有内在抵抗力的涂层 结垢和结垢可显著降低感染和不必要的发生率 疾病，允许更好地利用医疗资源，降低医疗成本，拯救生命。 结垢的原因是设备表面的生物膜中含有矿物质。这些沉积物抑制了 排水；是致命的细菌储存库；并增加局部组织对感染的敏感性。 抗生素策略已被证明在防止生物膜形成和结痂方面没有什么用处。 支架和导尿管。一种用于制造抗菌表面的技术是涂覆 当暴露在潮湿环境中时能够释放金属离子。抗菌银离子特别是 由于它们不会实质上被人体吸收的事实，对体内使用很有用。在第一阶段， Bright ton Technologies Group开发并表征了一种新型抗菌纳米涂层(AMNC) 基于气相沉积有效抑制生物膜的含银盐聚合物 形成的微生物范围很广。第二阶段将扩展这些结果，以创建一个 抗菌表面，可抑制医疗器械上生物膜的形成和结垢，例如 支架和留置导尿管通过： 1.开发在诸如输尿管支架等泌尿设备上沉积这些薄膜的技术， 福利导尿管和输尿管导管。 2.评价AMNC的重要特性，如疏水性/亲水性、系数 摩擦、附着力和耐磨性。 3.开发AMNC的活动和有效寿命的预测知识作为以下函数 结构和组成。 4.启动体内性能和生物相容性评估。

6. Project summary/abstract Nosocomial (hospital acquired) infections represent one of the most severe problems facing the health care industry. Of the approximately two million hospital acquired infections reported annually in this country, about half are associated with catheters, ureteral stents, central lines and other percutaneous devices that provide a support surface for organisms to track into deeper tissue. A typical infection can cost as much as $47,000 per patient to treat. Although invasive medical devices such as stents and catheters are pre-sterilized and inserted or implanted under the most sterile conditions available; biofilm growth, encrustation, and subsequent infection are the most common mode of failure. Coatings that could render these devices inherently resistant to biofilm formation and encrustation could significantly reduce the incidence of infections and unnecessary illness, allow better use of health care resources, reduce healthcare costs, and save lives. Encrustation results from mineral incorporation into biofilms on device surfaces. These deposits inhibit drainage; are virulent bacterial reservoirs; and increase susceptibility of the local tissues to infection. Antibiotic strategies have proven to be of little value in preventing biofilm formation and encrustation of stents and catheters. One technique for producing antimicrobial surfaces is to apply a coating which is capable of releasing metal ions when exposed to moisture. Antimicrobial silver ions are particularly useful for in vivo use due to the fact that they are not substantially absorbed into the body. In Phase I, Brighton Technologies Group developed and characterized a novel antimicrobial nanocoating (AMNC) based on gas-phase deposition of a silver salt-containing polymer that effectively inhibits biofilm formation for a wide range of microorganisms. Phase II will extend these results to create an antimicrobial surface that will inhibit biofilm formation and encrustation on medical devices such as stents and indwelling catheters through: 1. Developing techniques for depositing these films on urinary devices such as ureteral stents, Foley catheters, and ureteral catheters. 2. Evaluating important AMNC characteristics such as hydrophobicity/hydrophilicity, coefficient of friction, adhesion and wear resistance. 3. Developing predictive knowledge of activity and effective lifetime of AMNC's as a function of structure and composition. 4. Initiating in vivo performance and biocompatibility evaluations.